Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00374140 · ClinicalTrials.gov registry record · Phase 2
Phase II Trial of RAD001 (Everolimus) in Previously Treated Small Cell Lung Cancer
A Phase 2 study, sponsored by Ahmad Tarhini.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT00374140 is a Phase 2 study that has completed, run by Ahmad Tarhini. The registered enrollment target is 40 participants.
The verdict
NCT00374140, a Phase 2 study, has completed, sponsored by Ahmad Tarhini.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
This is a phase II, two-stage, open-label, single-agent study of the experimental drug RAD001 (everolimus) in patients with previously treated small cell lung cancer. RAD001 will be administered orally at a dose of 10 mg daily.
Interventions
- DRUG RAD001 (everolimus)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2006-10 |
| Est. Completion | 2012-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00374140
The ClinicalTrials.gov registry entry for NCT00374140 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ahmad Tarhini, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RAD001 (everolimus) is the first listed.
NCT00374140 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00374140 about?
NCT00374140 is a clinical study titled "Phase II Trial of RAD001 (Everolimus) in Previously Treated Small Cell Lung Cancer". This is a phase II, two-stage, open-label, single-agent study of the experimental drug RAD001 (everolimus) in patients with previously treated small cell lung cancer. RAD001 will be administered orally at a dose of 10 mg daily.
What is the current status of trial NCT00374140?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2006-10. Estimated completion is 2012-06.
What interventions are being tested in trial NCT00374140?
The interventions under investigation include: RAD001 (everolimus) (DRUG).
Who is sponsoring clinical trial NCT00374140?
This trial is sponsored by Ahmad Tarhini, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.